DNY59 CAH stock: unfavorable PEG ratio I last covered Cardinal Health (NYSE:CAH) stock a bit more than 3 months ago. As you can see from the chart below, my last article, titled "Cardinal Health: Solid Business But Overvalued", was published on April 18, 2024, and argued for a HOLD thesis on the stock. The holding rating was mainly based on the following considerations: Cardinal Health is overvalued, with a dividend yield lower than its historical average and a high P/E ratio. Growth projections for the ...

The latest trading session saw Cardinal Health (CAH) ending at $100.83, denoting a +0.57% adjustment from its last day's close. The stock fell short of the S&P 500, which registered a gain of 1.08% for the day. Meanwhile, the Dow gained 0.75%, and the Nasdaq, a tech-heavy index, added 2.64%. Coming into today, shares of the prescription drug distributor had gained 3.85% in the past month. In that same time, the Medical sector gained 0.71%, while the S&P 500 lost 0.44%. Market participants will be closely fo ...

Cardinal Health (CAH) closed the latest trading day at $96.71, indicating a +0.91% change from the previous session's end. The stock outperformed the S&P 500, which registered a daily loss of 2.32%. Elsewhere, the Dow saw a downswing of 1.25%, while the tech-heavy Nasdaq depreciated by 3.64%.The prescription drug distributor's shares have seen a decrease of 7.07% over the last month, not keeping up with the Medical sector's gain of 0.32% and the S&P 500's gain of 1.79%.Analysts and investors alike will be k ...

Cardinal Health’s (CAH) Presource kit plastic syringe makers Jiangsu Shenli Medical Production Co. Ltd and Jiangsu Caina have been facing FDA investigation. Recent inspections have unveiled multiple quality system violations, leading to warning letters and import alerts. CAH has recalled the affected products to ensure patient safety and compliance with FDA regulations.Following the recent warning, the import alert was expanded to preventJiangsu Shenli’s enteral syringes from entering the United States. The ...

DUBLIN, Ohio, July 23, 2024 /PRNewswire/ -- Cardinal Health (NYSE: CAH) plans to release fourth-quarter and year-end financial results for its fiscal year 2024 on August 14, prior to the opening of trading on the New York Stock Exchange. The company will webcast a discussion of these results beginning at 8:30 a.m. Eastern.To access the webcast and corresponding slide presentation, visit Cardinal Health's Investor Relations page. No access code is required. Presentation slides and a webcast replay will be av ...

Cardinal Health (CAH) ended the recent trading session at $95.97, demonstrating a +0.59% swing from the preceding day's closing price. The stock's performance was ahead of the S&P 500's daily loss of 1.39%. Elsewhere, the Dow saw an upswing of 0.6%, while the tech-heavy Nasdaq depreciated by 2.77%.Heading into today, shares of the prescription drug distributor had lost 8.34% over the past month, lagging the Medical sector's gain of 1.98% and the S&P 500's gain of 4.43% in that time.Market participants will ...

In the latest market close, Cardinal Health (CAH) reached $93.74, with a -0.38% movement compared to the previous day. The stock's performance was behind the S&P 500's daily gain of 0.28%. Elsewhere, the Dow saw an upswing of 0.53%, while the tech-heavy Nasdaq appreciated by 0.4%.The prescription drug distributor's shares have seen a decrease of 6.09% over the last month, not keeping up with the Medical sector's gain of 0.79% and the S&P 500's gain of 3.78%.Market participants will be closely following the ...

The latest trading session saw Cardinal Health (CAH) ending at $96.01, denoting a -0.9% adjustment from its last day's close. The stock trailed the S&P 500, which registered a daily gain of 0.07%. Elsewhere, the Dow saw a downswing of 0.13%, while the tech-heavy Nasdaq appreciated by 0.14%.Shares of the prescription drug distributor witnessed a loss of 1.98% over the previous month, beating the performance of the Medical sector with its loss of 1.99% and underperforming the S&P 500's gain of 4.34%.Analysts ...

Core Viewpoint - Neurocrine Biosciences has received FDA acceptance for two New Drug Applications (NDA) for crinecerfont, which could be the first new treatment for congenital adrenal hyperplasia (CAH) in 70 years, highlighting a significant advancement in addressing a serious endocrine disorder [1][2][3] Group 1: FDA Review and Designations - The FDA has set Prescription Drug User Fee Act (PDUFA) target action dates for the NDAs on December 29 and December 30, 2024, respectively [2] - Crinecerfont has been granted Priority Review designation, which accelerates the review timeline by four months, indicating the serious nature of CAH and the high unmet medical need [2][3] - The drug has also received Orphan Drug designation and Breakthrough Therapy designation, which provide various benefits including exemption from PDUFA fees and potential market exclusivity [3][4] Group 2: Clinical Data and Mechanism of Action - Crinecerfont is a selective corticotropin-releasing factor type 1 receptor (CRF1) antagonist aimed at reducing excess adrenocorticotropic hormone (ACTH) and adrenal androgens through a glucocorticoid-independent mechanism [8] - The CAHtalyst Phase 3 studies demonstrated strong efficacy and safety results, supporting the NDAs submitted to the FDA [4][9] - The drug aims to enable lower, more physiologic dosing of glucocorticoids, potentially reducing complications associated with higher doses currently used in treatment [8] Group 3: Background on Congenital Adrenal Hyperplasia - Congenital adrenal hyperplasia (CAH) is a rare genetic condition primarily caused by a deficiency of the enzyme 21-hydroxylase, leading to severe health issues if untreated [5] - Current treatments involve glucocorticoids at supraphysiologic doses, which can result in significant complications, including metabolic and psychological issues [6][7]

Richard Drury Welcome back to another edition of upcoming dividend increases. We are starting July's increases. If you are trading, be aware of the modified market hours next week. The market will close at 1 p.m. EST on the 3rd and be closed on July 4th. We also have dividend king Sysco Corporation extending its 54-year streak with a 2% increase. The overall group of companies has an average increase of 4.1% and a median of 3.7%. My investment strategy involves buying, holding, and adding to companies t ...